CareFirst opposes quick appeal in US antitrust case against Amgen
( November 3, 2025, 22:31 GMT | Official Statement) -- MLex Summary: CareFirst opposed Amgen’s petition for immediate appeal in a US antitrust case over the drug Enbrel, saying Amgen fails to establish that an interlocutory appeal would materially advance this case any more than it might materially advance any other case in which a district court denies a motion to dismiss. CareFirst said that Amgen’s motion repeats the key error from its motion to dismiss, which is to mischaracterize CareFirst’s claim as resting on protected petitioning activity while CareFirst really claims Amgen violated the antitrust laws by prosecuting patents before the patent office or asserting those patents in litigation.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.